Eli Lilly announced that the Phase 3 LIBRETTO-432 trial of Retevmo (selpercatinib) significantly improved event-free survival by reducing the risk of recurrence or death by 83% compared to placebo in early-stage RET fusion-positive non-small cell lung cancer patients. This is the first proven targeted adjuvant therapy for this patient group, highlighting the need for comprehensive biomarker testing at diagnosis. The results, to be published in the New England Journal of Medicine and presented at the 2026 ASCO Annual Meeting, may change clinical practice by establishing Retevmo as a new standard of care after surgery or radiation.
Eli Lilly has begun construction on a $3.5 billion manufacturing facility in Pennsylvania's Lehigh Valley to produce injectable medicines, including the next-generation obesity treatment retatrutide. The site will create 850 high-wage jobs and about ...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
Eli Lilly's TOGETHER-PsA Phase 3b trial showed that combining Taltz (ixekizumab) and Zepbound (tirzepatide) nearly tripled the number of patients achieving at least 50% reduction in psoriatic arthritis (PsA) disease activity after one year compared t...
Hims & Hers reported a surprise Q3 loss and cut its full-year profit outlook, causing its stock to drop 18%. Despite 48.6% revenue growth, the company missed revenue estimates and faced margin pressure due to lower-margin weight-loss products and int...
Hims & Hers stock dropped 25.67% in a week following its deal with Eli Lilly to expand access to weight-loss drugs, despite Lilly's modest share gains. The decline reflects challenges from Hims' shift to branded GLP-1 drugs, including a drop in gross...
